Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.
Int J Lab Hematol. 2019 Aug;41(4):513-518. doi: 10.1111/ijlh.13035. Epub 2019 May 17.
Most β-thalassemia carriers have hypochromic microcytosis with mean corpuscular volume (MCV) < 80 fL and mean corpuscular hemoglobin (MCH) < 27 pg. These can be variable due to β-thalassemia mutations, genetic interaction between thalassemic genes, and blood cell counters. We have examined whether these indices are effective in screening of β-thalassemia in Thailand where thalassemia is prevalence and heterogeneous.
Retrospective data were reviewed on 11 443 Thai subjects encountered from August 2014 to August 2017. Subjects with heterozygous β-thalassemia based on Hb and DNA analyses were recruited along with MCV and MCH values and analyzed.
Among the 11 443 subjects reviewed, 1425 were β-thalassemia carriers. Data were available on 1214 subjects for MCV and 965 subjects for MCH. DNA analysis identified 20 different β -thalassemia mutations in 874 (72.0%) cases and 6 β -thalassemia mutations in 340 (28.0%) subjects. Of these 1214 carriers, 26 (2.1%) had MCV ≥ 80 fL; 6 (23.1%) carried β -thalassemia, and the remaining 20 (76.9%) had β -thalassemia. In contrast for those having MCH values, only 4 of 965 (0.4%) had MCH ≥ 27 pg. DNA analysis identified both β -thalassemia and β -thalassemia mutations.
Using MCV alone for the screening of β-thalassemia may pose a significant number of false negative although three-quarter of them are carriers of mild β -thalassemia. MCH with approximately five times more sensitive is a better screening marker. Using a combined MCV and MCH is highly recommended, especially in an area with high prevalence and heterogeneity of thalassemia like Thailand.
大多数β-地中海贫血携带者表现为低色素小红细胞,平均红细胞体积(MCV)<80fL,平均红细胞血红蛋白(MCH)<27pg。这些数值可能因β-地中海贫血突变、地中海贫血基因间的遗传相互作用和血细胞计数器而有所变化。我们已经研究了这些指标在泰国β-地中海贫血筛查中的有效性,因为泰国的地中海贫血患病率高且呈异质性。
回顾性分析了 2014 年 8 月至 2017 年 8 月期间遇到的 11443 例泰国受试者的数据。根据 Hb 和 DNA 分析招募了杂合子β-地中海贫血患者,并检测了 MCV 和 MCH 值。
在 11443 例受试者中,有 1425 例为β-地中海贫血携带者。有 1214 例受试者的 MCV 值和 965 例受试者的 MCH 值可供分析。DNA 分析在 874 例(72.0%)病例中确定了 20 种不同的β-地中海贫血突变,在 340 例(28.0%)受试者中确定了 6 种β-地中海贫血突变。在这 1214 名携带者中,有 26 名(2.1%)的 MCV≥80fL;6 名(23.1%)携带β-地中海贫血,其余 20 名(76.9%)为β-地中海贫血。相比之下,在 MCH 值方面,只有 965 例(0.4%)的患者 MCH≥27pg。DNA 分析同时确定了β-地中海贫血和β-地中海贫血突变。
虽然其中四分之三为轻度β-地中海贫血携带者,但单独使用 MCV 筛查β-地中海贫血可能会导致大量假阴性。大约五倍于 MCH 的敏感性是更好的筛查标志物。建议使用 MCV 和 MCH 联合检测,特别是在泰国等地中海贫血患病率高且呈异质性的地区。